Michael David Garrison Sells 1,100 Shares of Becton, Dickinson and Company (NYSE:BDX) Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president directly owned 13,172 shares of the company’s stock, valued at $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael David Garrison also recently made the following trade(s):

• On Wednesday, June 10th, Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $151.48, for a total value of $166,628.00.

Becton, Dickinson and Company Trading Up 3.1%

Shares of Becton, Dickinson and Company stock opened at $156.06 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $43.00 billion, a P/E ratio of 39.51, a price-to-earnings-growth ratio of 10.72 and a beta of 0.22. The stock has a fifty day simple moving average of $148.17 and a 200 day simple moving average of $170.75. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. During the same quarter in the prior year, the business posted $3.35 EPS. The business’s revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 106.33%.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of research analyst reports. Wells Fargo & Company increased their price target on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. Royal Bank Of Canada set a $175.00 price objective on Becton, Dickinson and Company in a research note on Tuesday, April 14th. Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Argus cut their price target on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a report on Monday, March 23rd. Finally, Barclays raised their price objective on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Seven analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and a consensus price target of $181.00.

Institutional Trading of Becton, Dickinson and Company

A number of large investors have recently bought and sold shares of BDX. Brighton Jones LLC lifted its stake in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares in the last quarter. Graybill Wealth Management LTD. raised its holdings in Becton, Dickinson and Company by 47.3% during the 3rd quarter. Graybill Wealth Management LTD. now owns 27,592 shares of the medical instruments supplier’s stock valued at $5,164,000 after acquiring an additional 8,859 shares during the period. Skba Capital Management LLC lifted its position in shares of Becton, Dickinson and Company by 1,619.9% during the third quarter. Skba Capital Management LLC now owns 57,514 shares of the medical instruments supplier’s stock worth $10,765,000 after acquiring an additional 54,170 shares in the last quarter. Danske Bank A S bought a new position in shares of Becton, Dickinson and Company in the third quarter worth $34,596,000. Finally, Elo Mutual Pension Insurance Co grew its position in shares of Becton, Dickinson and Company by 24.7% in the third quarter. Elo Mutual Pension Insurance Co now owns 34,609 shares of the medical instruments supplier’s stock valued at $6,478,000 after purchasing an additional 6,856 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.